Last 48 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Amphastar Pharmaceuticals, Inc.'s quarterly P/E stands at 35.0x, up 146.3% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has expanded 64.1% YoY to 15.0x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 11.84 | 35.00 | 13.13 | 18.01 | 8.97 | 14.21 | 12.54 | 15.55 | 13.70 | 13.55 | 22.74 | 12.63 | 29.32 |
| — | +146.3% | +4.7% | +15.8% | -34.5% | +4.9% | -44.8% | +23.1% | -53.3% | -27.7% | +114.2% | -46.0% | +11.3% | |
| P/S Ratio | 1.49 | 1.33 | 1.72 | 1.66 | 1.58 | 2.12 | 2.59 | 3.33 | 2.85 | 3.39 | 4.60 | 3.43 | 5.24 |
| — | -37.3% | -33.4% | -50.3% | -44.5% | -37.4% | -43.7% | -2.9% | -45.5% | -2.7% | +71.5% | +11.2% | +39.6% | |
| P/B Ratio | 1.47 | 1.18 | 1.60 | 1.64 | 1.46 | 1.93 | 2.64 | 3.46 | 2.92 | 3.46 | 5.13 | 4.17 | 5.18 |
| — | -38.8% | -39.3% | -52.7% | -50.0% | -44.4% | -48.5% | -17.0% | -43.7% | -2.5% | +87.1% | +41.9% | +39.7% | |
| P/FCF | 8.83 | 5.94 | 12.84 | 6.72 | 11.04 | 14.83 | 29.09 | 13.63 | 8.25 | 12.52 | 56.84 | 11.45 | 16.63 |
| — | -60.0% | -55.9% | -50.7% | +33.8% | +18.5% | -48.8% | +19.0% | -50.4% | -20.6% | +39.9% | -54.4% | — | |
| EV / EBITDA | 10.44 | 14.97 | 11.34 | 10.84 | 6.73 | 9.12 | 10.17 | 10.33 | 9.06 | 11.11 | 13.86 | 8.36 | 19.52 |
| — | +64.1% | +11.6% | +4.9% | -25.7% | -17.9% | -26.7% | +23.5% | -53.6% | -3.2% | +79.9% | -28.5% | +38.1% | |
| EV / EBIT | 11.08 | — | 11.34 | 15.39 | 8.62 | 12.89 | 12.07 | 13.58 | 10.67 | 14.34 | 18.50 | 9.33 | 23.55 |
| — | — | -6.0% | +13.3% | -19.2% | -10.1% | -34.8% | +45.6% | -54.7% | +4.0% | +121.5% | -39.5% | +24.0% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Amphastar Pharmaceuticals, Inc.'s operating margin was 8.0% in Q1 2026, down 11.5 pp QoQ and down 13.9 pp YoY. The trailing four-quarter average of 16.2% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 17.8% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 49.5% | 41.1% | 46.8% | 51.4% | 49.6% | 50.0% | 46.5% | 54.0% | 52.2% | 50.8% | 54.0% | 60.0% | 49.9% |
| — | -17.8% | +0.7% | -4.8% | -5.0% | -1.6% | -13.9% | -10.1% | +4.5% | -3.7% | +2.4% | +23.3% | -2.7% | |
| Operating Margin | 19.5% | 8.0% | 19.4% | 13.2% | 24.2% | 21.9% | 24.2% | 30.2% | 30.3% | 27.9% | 30.3% | 40.3% | 25.3% |
| — | -63.6% | -19.7% | -56.3% | -20.1% | -21.7% | -20.1% | -24.9% | +19.6% | +17.0% | +8.2% | +108.2% | +25.9% | |
| Net Margin | 13.6% | 3.8% | 13.3% | 9.0% | 17.8% | 14.8% | 20.4% | 21.4% | 20.8% | 25.1% | 20.3% | 27.3% | 17.9% |
| — | -74.7% | -34.5% | -57.8% | -14.5% | -41.0% | +0.2% | -21.5% | +16.1% | +35.2% | -19.2% | +106.3% | +27.6% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 12.9% | 0.8% | 3.1% | 2.3% | 4.1% | 3.4% | 5.2% | 5.6% | 5.5% | 6.6% | 5.9% | 8.3% | 4.6% |
| — | -75.9% | -40.0% | -59.7% | -24.9% | -48.2% | -11.2% | -32.5% | +19.3% | +36.2% | -10.7% | +163.0% | +29.6% | |
| ROA | 6.1% | 0.4% | 1.5% | 1.1% | 1.9% | 1.6% | 2.4% | 2.7% | 2.5% | 2.8% | 2.4% | 3.4% | 2.4% |
| — | -75.2% | -39.0% | -60.3% | -22.7% | -43.6% | +2.8% | -20.9% | +2.0% | -18.6% | -48.8% | +53.9% | +0.8% | |
| ROIC | 8.4% | 1.0% | 2.1% | 1.6% | 2.6% | 2.3% | 2.8% | 3.7% | 3.7% | 3.2% | 3.8% | 5.5% | 3.8% |
| — | -54.1% | -24.1% | -58.0% | -30.0% | -29.8% | -26.0% | -33.1% | -3.9% | -38.5% | -37.7% | +41.2% | -12.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Amphastar Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 5.6x, down from 17.0x last quarter — elevated, raising questions about debt serviceability. The current ratio has improved 30.4% YoY to 3.85x, strengthening the short-term liquidity position. Debt/Equity has declined for 6 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.83 | 0.10 | 0.83 | 0.85 | 0.87 | 0.87 | 0.89 | 0.87 | 0.87 | 0.93 | 0.98 | 1.13 | 0.90 |
| — | -88.6% | -6.4% | -2.3% | -0.5% | -6.9% | -8.9% | -23.4% | -3.1% | +401.5% | +402.6% | +453.0% | +331.1% | |
| Debt / EBITDA | 4.40 | 5.62 | 17.02 | 16.65 | 11.22 | 12.43 | 10.88 | 8.81 | 8.95 | 10.12 | 9.20 | 7.80 | 12.04 |
| — | -54.8% | +56.5% | +88.9% | +25.4% | +22.8% | +18.2% | +13.0% | -25.7% | +305.0% | +306.1% | +130.8% | +266.7% | |
| Current Ratio | 4.02 | 3.85 | 4.02 | 3.12 | 3.29 | 2.95 | 3.07 | 3.43 | 3.52 | 2.18 | 2.17 | 2.10 | 1.53 |
| — | +30.4% | +30.8% | -9.2% | -6.6% | +35.8% | +41.5% | +63.1% | +130.3% | -43.6% | -45.5% | -44.0% | -57.9% | |
| Quick Ratio | 2.90 | 2.82 | 2.90 | 2.21 | 2.21 | 2.02 | 2.19 | 2.61 | 2.63 | 1.72 | 1.70 | 1.68 | 1.11 |
| — | +39.4% | +32.6% | -15.5% | -16.1% | +17.4% | +28.6% | +55.7% | +136.1% | -40.1% | -41.2% | -38.9% | -58.5% | |
| Interest Coverage | 5.85 | 2.08 | 5.81 | 4.42 | 7.26 | 5.91 | 7.84 | 8.12 | 6.84 | 5.58 | 5.37 | 5.64 | 10.11 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying AMPH stock.
Amphastar Pharmaceuticals, Inc.'s current P/E is 11.8x. The average P/E over the last 4 quarters is 18.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Amphastar Pharmaceuticals, Inc.'s current operating margin is 19.5%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Amphastar Pharmaceuticals, Inc.'s business trajectory between earnings reports.